Literature DB >> 31736094

Prognostic significance of nucleolar assessment in invasive breast cancer.

Khloud A Elsharawy1,2, Michael S Toss1, Sara Raafat1, Graham Ball3, Andrew R Green1, Mohammed A Aleskandarany1, Leslie W Dalton4, Emad A Rakha1.   

Abstract

AIMS: Nucleolar morphometric features have a potential role in the assessment of the aggressiveness of many cancers. However, the role of nucleoli in invasive breast cancer (BC) is still unclear. The aims of this study were to investigate the optimal method for scoring nucleoli in IBC and their prognostic significance, and to refine the grading of breast cancer (BC) by incorporating nucleolar score. METHODS AND
RESULTS: Digital images acquired from haematoxylin and eosin-stained sections from a large BC cohort were divided into training (n = 400) and validation (n = 1200) sets for use in this study. Four different assessment methods were evaluated in the training set to identify the optimal method associated with the best performance and significant prognostic value. These were: (i) a modified Helpap method; (ii) counting prominent nucleoli (size ≥2.5 µm) in 10 field views (FVs); (iii) counting prominent nucleoli in five FVs; and (iv) counting prominent nucleoli in one FV. The optimal method was applied to the validation set and to an external validation set, i.e. data from The Cancer Genome Atlas (n = 743). Scoring prominent nucleoli in five FVs showed the highest interobserver concordance rate (intraclass correlation coefficient of 0.8) and a significant association with BC-specific survival (P < 0.0001). A high nucleolar score was associated with younger age, larger tumour size, and higher grade. Incorporation of nucleolar score in the Nottingham grading system resulted in a higher significant association with survival than the conventional grade.
CONCLUSIONS: Quantification of nucleolar prominence in five FVs is a cost-efficient and reproducible morphological feature that can predict BC behaviour and can provide an alternative to pleomorphism to improve BC grading performance.
© 2019 Crown copyright. Histopathology © 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  invasive breast cancer; methods; nucleoli; prognosis

Mesh:

Year:  2020        PMID: 31736094     DOI: 10.1111/his.14036

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  5 in total

1.  Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma.

Authors:  Jean-Christophe Tille; André F Vieira; Caroline Saint-Martin; Lounes Djerroudi; Laëtitia Furhmann; Francois-Clement Bidard; Youlia Kirova; Anne Tardivon; Fabien Reyal; Matthieu Carton; Anne Vincent-Salomon
Journal:  Mod Pathol       Date:  2020-05-13       Impact factor: 7.842

2.  Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer.

Authors:  Khloud A Elsharawy; Maryam Althobiti; Omar J Mohammed; Abrar I Aljohani; Michael S Toss; Andrew R Green; Emad A Rakha
Journal:  Breast Cancer Res Treat       Date:  2020-11-08       Impact factor: 4.872

3.  Krüppel-like factor 7 influences translation and pathways involved in ribosomal biogenesis in breast cancer.

Authors:  Anne-Marie Lüchtenborg; Patrick Metzger; Miguel Cosenza Contreras; Victor Oria; Martin L Biniossek; Franziska Lindner; Klemens Fröhlich; Ambrus Malyi; Thalia Erbes; Nicole Gensch; Jochen Maurer; Andreas Thomsen; Melanie Boerries; Oliver Schilling; Martin Werner; Peter Bronsert
Journal:  Breast Cancer Res       Date:  2022-10-03       Impact factor: 8.408

4.  The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer.

Authors:  Khloud A Elsharawy; Omar J Mohammed; Mohammed A Aleskandarany; Ayman Hyder; Hekmat L El-Gammal; Mohamed I Abou-Dobara; Andrew R Green; Leslie W Dalton; Emad A Rakha
Journal:  Br J Cancer       Date:  2020-09-01       Impact factor: 9.075

Review 5.  Ribosomal RNA Transcription Regulation in Breast Cancer.

Authors:  Cecelia M Harold; Amber F Buhagiar; Yan Cheng; Susan J Baserga
Journal:  Genes (Basel)       Date:  2021-03-29       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.